A statement released earlier today by Vetr Inc. about Amgen, Inc. (NASDAQ:AMGN) bumps the target price to $188.11
- Updated: September 29, 2016
Vetr Inc. bumped up the target of Amgen, Inc. (NASDAQ:AMGN) to $188.11 stating a potential upside of 0.13%.
On 9/28/2016, Citigroup released a statement for Amgen, Inc. (NASDAQ:AMGN) bumped down the target price from $175.00 to $172.00 that suggested an upside of 0.01%.
Boasting a price of $166.10, Amgen, Inc. (NASDAQ:AMGN) traded -2.51% lower on the day. With the last stock price close up 2.85% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Amgen, Inc. has recorded a 50-day average of $171.84 and a two hundred day average of $160.86. Volume of trade was up over the average, with 3,803,974 shares of AMGN changing hands over the typical 2,841,400
With a total market value of $0, Amgen, Inc. has 52 week low of $135.64 and a 52 week high of $176.85 with a P/E ratio of 16.93 .
In addition to Vetr Inc. reporting its target price, a total of 17 firms have reported on the stock. The consensus target price is $183.88 with 2 firms rating the stock a strong buy, 9 firms rating the stock a buy, 10 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Amgen, Inc. (NASDAQ:AMGN)
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.